Computational simulations establish a novel transducer array placement arrangement that extends delivery of therapeutic TTFields to the infratentorium of patients with brainstem gliomas
Abstract
Background and Purpose: Tumor treating fields (TTFields) are a non-invasive, efficacious treatment modality currently approved for supratentorial glioblastomas. Despite their ability to improve overall survival in supratentorial tumors, the current placement of arrays is limited to the supratentorial head, precluding its use in infratentorial tumors. Infratentorial malignancies are in need of new therapy modalities given their poor prognoses in both children and adults. The aim of this research is to determine whether rearrangement of TTFields may allow for management of infratentorial tumors.
Materials and methods: Delivery of TTFields using Novocure’s prototype Optune™ device human male head model was simulated based on brain MRIs from patients with brainstem gliomas to develop a novel array layout designed to extend adequate infratentorial coverage.
Results: Array placement on the vertex, bilateral posterolateral occiput, and superior-posterior neck achieved intensities above 1.1 V/cm (average 1.7 V/cm; maximum 2.3 V/cm) in the vertical field direction and above 1 V/cm (average 2 V/cm; maximum 2.8 V/cm) in the horizontal field direction of the infratentorium. The calculated field intensity within the simulated tumors were in the therapeutic range and demonstrated the effective delivery of TTFields to the infratentorial brain.
Conclusions: Our findings suggest that rearrangement of the TTFields standard array with placement of electrodes on the vertex, bilateral posterolateral occiput, and superior-posterior neck allows for adequate electric field distribution in the infratentorium that is within the therapeutic range.
Keywords: tumor treating fieldsbrainstem gliomainfratentorial deliverysimulation array
References
- Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012; 48(14): 2192–2202.
- Stupp R, Taillibert S, Kanner A, et al. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. JAMA. 2015; 314(23): 2535.
- U.S. Food and Drug Administration. FDA approves expanded indication for medical device to treat a form of brain cancer (FDA Press Announcement No. 4658744). 2015. htps://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465744.htm. (January 13, 2018.).
- Hu J, Western S, Kesari S. Brainstem Glioma in Adults. Front Oncol. 2016; 6: 180.
- Kirson E, Gurvich Z, Schneiderman R, et al. Disruption of Cancer Cell Replication by Alternating Electric Fields. Cancer Res. 2004; 64(9): 3288–3295.
- Kirson ED, Dbalý V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007; 104(24): 10152–10157.
- McClelland S3, Sosanya O, Mitin T, et al. Sosanya O, Mitin T, Application of tumor treating fields for newly diagnosed glioblastoma: understanding of nationwide practice paterns. J Neurooncol. 2018; 140(1): 155–158.
- McClelland S3, Henrikson CA, Ciporen JN, et al. Tumor treating fields utilization in a glioblastoma patient with a preexisting cardiac pacemaker: the first reported case. World Neurosurg. 2018; 119: 58–60.
- Lok E, San P, Liang O, et al. Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma. J Neurooncol. 2020; 147(1): 125–133.